General
Preferred name
EXENATIDE
Synonyms
Byetta ()
extenatide ()
Exendin-4 (48-86) amide (acetate) ()
LY-2148568 ()
Bydureon bcise ()
Bydureon pen ()
ITCA-650 ()
AC 2993 ()
Exendin 4 ()
Exenatida ()
AC2993A ()
EXENDIN-4 ()
DA-3091 ()
AC-2993A ()
AC-2993LAR ()
AC2993 ()
AC-2993 ()
LY2148568 ()
Bydureon ()
AC-002993 ()
Exenatide Synthetic ()
AC002993 ()
P&D ID
PD071714
CAS
141758-74-9
914454-01-6
Tags
available
drug
Approved by
FDA
First approval
2005
Drug indication
Type-2 diabetes
Cardiovascular disease
diabetes mellitus
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
10
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Natural product-based probes and drugs
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
4184.03
Hydrogen Bond Acceptors
60
Hydrogen Bond Donors
58
Rotatable Bonds
134
Ring Count
9
Aromatic Ring Count
5
cLogP
-20.6
TPSA
1749.75
Fraction CSP3
0.61
Chiral centers
37.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
diabetes mellitus
Target
GLP1R
MOA
GLP receptor agonist
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antidiabetic
Therapeutic Class
Metabolic Disorders
Hypoglycemic Agents
Source data
